In-licensing. Bionaturis is looking for the following technologies/products to be incorporated into its R&D or production programs:
- Recombinant proteins purification. New approaches for purification of biopharmaceuticals (in compliance with industrial and regulatory requirements)
- Baculovirus expressed second generation vaccines. We look for second generation vaccines (based on recombinant proteins) successfully expressed by means of baculovirus expression vector systems. Patent protection and both in-vitro and in-vivo tests are mandatory.
Out-licensing. Bionaturis is keen to reach out-license agreements of its technologies/products listed below:
FLYLIFE Plug&Play technology platform
FLYLIFE licensing can be adapted to each partner need, using the following license structure:
- Non-Exclusive, Research Only license
- Non-Exclusive, Research and Development license (up to non-clinical studies -tox material-)
- Exclusive Production License
BNT004: Intranasal formulation based on inclusion bodies of a recombinant protein of the gene pph-1 of Angiostrongylus costaricensis
Indication
Prophylactic vaccine to generate a broad immune response against the infection of nematode parasites in cattle
Development stage
Efficacy and toxicity tested in rodents and lambs. Broad protection.
BNT005: Adjuvanted recombinant subunit vaccine based on a flagellar protein from a leishmania causing agent to be administered intramuscular/deep SC
Indication
Prophylactic and therapeutic vaccine against canine visceral leishmaniasis
Development stage
Efficacy and toxicity tested in rodent challenges. Dog trials planned (Q12013)